Bal Pharma Limited

As of June 30, 2026, Bal Pharma Limited carries a market capitalization of 1.27B, placing it among publicly traded companies globally. Its enterprise value stands at 1.27B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Bal Pharma Limited has 15.92M shares outstanding.

As of June 30, 2026, Bal Pharma Limited trades at a trailing price-to-earnings ratio of 17.49.

As of June 30, 2026, Bal Pharma Limited trades at an EV/EBITDA multiple of 3.75 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.38 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 5.64 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.27B versus a market cap of 1.27B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 3.47M in revenue per employee across its workforce of 962.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Bal Pharma Limited recorded an income tax benefit of -3.86M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 68.63M, leaving 72.06M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Bal Pharma Limited's stock has gained approximately 4.02% over the past 52 weeks. The 50-day moving average sits at 95.67, while the 200-day moving average is 82.33.

Over the twelve months ended June 30, 2026, Bal Pharma Limited generated 3.34B in revenue and converted that into 72.06M in net income, yielding earnings per share of 4.57. EBITDA reached 337.91M, while operating income came in at 224.50M.

Over the twelve months ended June 30, 2026, Bal Pharma Limited posted a gross margin of 47.50, reflecting its pricing power and cost economics. The operating margin of 6.71 and net profit margin of 2.15 provide insight into operational efficiency.

Bal Pharma Limited's most recent stock split took place on April 7, 2005.